Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.42 |
| ▸ | SIRT1 | Q96EB6 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.38 |
| ▸ | PRNP | P04156 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | PPARG | P37231 | 1/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | NR2E3 | Q9Y5X4 | 1/20 | 0.38 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 3/20 | 0.35 |
| ▸ | CA2 | P00918 | 3/20 | 0.35 |
| ▸ | CA12 | O43570 | 2/20 | 0.35 |
| ▸ | CA9 | Q16790 | 2/20 | 0.35 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2931903 | 0.89 | RXFP1 (0.46) | RXFP1SIRT1CYP1A2CYP2C19PRNP | |
| SCHEMBL2924649 | 0.89 | RXFP1 (0.46) | RXFP1SIRT1CYP1A2CYP2C19PRNP | |
| SCHEMBL2925201 | 0.86 | MAP2 (0.49) | SIRT1 | |
| SCHEMBL2927638 | 0.86 | CA1 (0.35) | CA1CA2CA12CA9CDK1 | |
| SCHEMBL2924397 | 0.86 | ALDH1A1 (0.41) | RXFP1SIRT1CYP1A2CYP2C19PRNP | |
| SCHEMBL3606849 | 0.86 | RXFP1 (0.40) | RXFP1SIRT1CYP1A2CYP2C19PRNP | |
| SCHEMBL3606479 | 0.86 | MAPK1 (0.43) | RXFP1SIRT1CYP1A2CYP2C19PRNP | |
| SCHEMBL3609170 | 0.85 | MAPK1 (0.45) | RXFP1SIRT1CYP1A2CYP2C19PRNP | |
| SCHEMBL3614435 | 0.84 | RXFP1 (0.40) | RXFP1SIRT1CYP1A2CYP2C19PRNP | |
| SCHEMBL3609347 | 0.84 | SIRT1 (0.40) | RXFP1SIRT1CYP1A2CYP2C19PRNP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1534695-B1 | TYROSINE KINASE INHIBITORS | MERCK SHARP & DOHME (US) | 2010-09-29 | — | — | EP | claimed |
| US-7560546-B2 | Tyrosine kinase inhibitors | MERCK & CO., INC. (US) | 2009-07-14 | — | — | US | claimed |
| EP-1534695-A4 | TYROSINE KINASE INHIBITORS | MERCK & CO INC (US) | 2008-06-11 | — | — | EP | claimed |
| US-20050261496-A1 | Tyrosine kinase inhibitors | MERCK SHARP & DOHME LLC | 2005-11-24 | — | — | US | claimed |
| EP-1534695-A2 | TYROSINE KINASE INHIBITORS | Merck & Co., Inc. (US) | 2005-06-01 | — | — | EP | claimed |
| US-20040102360-A1 | Combination therapy | BARNETT STANLEY F (US) | 2004-05-27 | — | — | US | claimed |
| WO-2004014851-A2 | TYROSINE KINASE INHIBITORS | MERCK & CO., INC. (US) | 2004-02-19 | — | — | WO | claimed |
| EP-1534695-B1 | TYROSINE KINASE INHIBITORS | MERCK SHARP & DOHME (US) | 2010-09-29 | — | — | EP | disclosed |
| US-20090186871-A1 | Tyrosine kinase inhibitors | MERCK SHARP & DOHME CORP. | 2009-07-23 | — | — | US | disclosed |
| US-20090186871-A1 | Tyrosine kinase inhibitors | MERCK SHARP & DOHME CORP. | 2009-07-23 | — | — | US | disclosed |
| US-20090186871-A1 | Tyrosine kinase inhibitors | MERCK SHARP & DOHME CORP. | 2009-07-23 | — | — | US | disclosed |
| US-7560546-B2 | Tyrosine kinase inhibitors | MERCK & CO., INC. (US) | 2009-07-14 | — | — | US | disclosed |
| US-7560546-B2 | Tyrosine kinase inhibitors | MERCK & CO., INC. (US) | 2009-07-14 | — | — | US | disclosed |
| US-7560546-B2 | Tyrosine kinase inhibitors | MERCK & CO., INC. (US) | 2009-07-14 | — | — | US | disclosed |
| EP-1534695-A4 | TYROSINE KINASE INHIBITORS | MERCK & CO INC (US) | 2008-06-11 | — | — | EP | disclosed |
| US-20050261496-A1 | Tyrosine kinase inhibitors | MERCK SHARP & DOHME LLC | 2005-11-24 | — | — | US | disclosed |
| EP-1534695-A2 | TYROSINE KINASE INHIBITORS | Merck & Co., Inc. (US) | 2005-06-01 | — | — | EP | disclosed |
| US-20040102360-A1 | Combination therapy | BARNETT STANLEY F (US) | 2004-05-27 | — | — | US | disclosed |
| WO-2004014851-A2 | TYROSINE KINASE INHIBITORS | MERCK & CO., INC. (US) | 2004-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050261496-A1 | Tyrosine kinase inhibitors | ABL1, JAK2, ERBB2 | RXFP1 706/4885SIRT1 2309/4885CYP1A2 3059/4885 |
| US-20040102360-A1 | Combination therapy | MTOR, AKT2, PLK1 | RXFP1 4667/4885SIRT1 1401/4885CYP1A2 4768/4885 |
| US-20090186871-A1 | Tyrosine kinase inhibitors | ABL1, JAK2, ERBB2 | RXFP1 706/4885SIRT1 2309/4885CYP1A2 3059/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.